Eli Lilly Fights Back Against Compounded Tirzepatide Amid FDA Supply Resolution

Eli Lilly issues cease-and-desist letters to stop the sale of compounded tirzepatide as the FDA declares the drug's shortage resolved.

Eli Lilly has sent cease-and-desist letters to compounding pharmacies to halt the production of non-name-brand tirzepatide, citing the FDA's resolution of the drug's shortage.
The FDA removed tirzepatide from its shortage list on October 2, 2024, after confirming Eli Lilly's ability to meet national demand.
Compounding pharmacies and telehealth companies have been producing cheaper versions of tirzepatide during the shortage, leading to legal disputes.
The Outsourcing Facilities Association has filed a lawsuit against the FDA, challenging the decision to end the shortage status of tirzepatide.
Eli Lilly's legal actions highlight the tension between pharmaceutical companies and compounders over the production and sale of GLP-1 medications.